Physicians' Academy for Cardiovascular Education
A prespecified analysis of the DELIVER trial showed early (<2 weeks) and sustained (>2 years) reductions in CV death or worsening HF with dapagliflozin compared with placebo in patients with HFmrEF or HFpEF.
The EMPEROR-Preserved trial showed that empagliflozin reduced the risk of CV death or HF hospitalization in patients with HF and LVEF >40%. However, it is unknown whether the effect of empagliflozin differs between patients with HFmrEF and those with HFpEF. This subgroup analysis of the EMPEROR-Preserved trial offers more clarity.
In patients with HFmrEF or HFpEF, the efficacy and safety of dapagliflozin were not influenced by background treatment with an MRA or ARNI, as shown by a prespecified analysis of the DELIVER trial.
In 530 patients hospitalized for acute HF, empagliflozin treatment resulted in early, clinically meaningful decongestion compared with placebo. The magnitude of decongestion was associated with clinical benefit at day 90.
Prof. Kosiborod reviews the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes in patients with heart failure and concomitant kidney dysfunction and/or diabetes.
AHA 2022 In the EMPA-KIDNEY trial, use of empagliflozin reduced the outcome of worsening of kidney disease or CV death compared with placebo in CKD patients. In addition, results of a meta-analysis of 13 SGLT2i trials in high-risk patients were presented.
AHA 2022 David Preiss shares the results from the EMPA-KIDNEY trial and a collaborative meta-analysis including EMPA-KIDNEY and 12 other major SGLT2i trials.
The observational cohort study EVOLUTION HF showed delayed initiation of novel guideline-directed medical therapies (GDMTs) after HHF in HFrEF patients in Japan, Sweden, and the USA, compared with other GDMTs.
The DELIVER trial investigated the effects of dapagliflozin in patients with HF and LVEF > 40%. Prof. Inzucchi shows the primary results from DELIVER and presents an update based on glycemic subgroups in the trial.
What are the current and potential future options in the precision management of patients with atherosclerotic cardiovascular disease? Prof. Landmesser presents these options per segment.
By analysis of pooled plasma samples of 1134 patients from the EMPEROR-Reduced and EMPEROR-Preserved trials using large-scale proteomics, the authors identified several biological effects of empagliflozin on the heart and kidneys.
In the EMMY trial, empagliflozin treatment started within 72 hours after PCI was associated with a greater NT-proBNP decline and improved echocardiographic parameters at 26 weeks in AMI patients, without evident safety risks.
